Last $13.76 USD
Change Today -0.06 / -0.43%
Volume 45.8K
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

esperion therapeutics inc (ESPR) Snapshot

Open
$13.80
Previous Close
$13.82
Day High
$14.44
Day Low
$13.37
52 Week High
08/13/13 - $20.10
52 Week Low
11/27/13 - $10.90
Market Cap
211.8M
Average Volume 10 Days
51.8K
EPS TTM
$-5.55
Shares Outstanding
15.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ESPERION THERAPEUTICS INC (ESPR)

Related News

No related news articles were found.

esperion therapeutics inc (ESPR) Related Businessweek News

No Related Businessweek News Found

esperion therapeutics inc (ESPR) Details

Esperion Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. Its products include ETC-1002, an oral molecule therapy that is in Phase IIb clinical trials to treat lipid and carbohydrate metabolic pathways; ESP41091, which is in pre-clinical trials for type 2 diabetes and obesity treatment; and 4WF, a synthetic apoA-I therapy that is in pre-clinical trials for treating patients with acute coronary syndrome. The company is headquartered in Plymouth, Michigan.

16 Employees
Last Reported Date: 03/13/14

esperion therapeutics inc (ESPR) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $400.0K
Vice President of Business Development
Total Annual Compensation: $200.8K
Senior Advisor to Chief Executive Officer
Total Annual Compensation: $335.0K
Executive Chairman and Chief Scientific Offic...
Total Annual Compensation: $375.0K
Compensation as of Fiscal Year 2013.

esperion therapeutics inc (ESPR) Key Developments

Esperion Therapeutics, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 08:40 AM

Esperion Therapeutics, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 08:40 AM. Venue: The Westin Grand Central Hotel, New York, New York, United States.

Esperion Therapeutics, Inc. Presents at The 21st Annual Future Leaders in the Biotech Industry Conference, Mar-28-2014 02:30 PM

Esperion Therapeutics, Inc. Presents at The 21st Annual Future Leaders in the Biotech Industry Conference, Mar-28-2014 02:30 PM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States. Speakers: Timothy M. Mayleben, Chief Executive Officer, President, Principal Financial Officer and Director.

Esperion Therapeutics, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Cash Flow Guidance for the Full Year 2014; Provides ETC-1002 Program Update

Esperion Therapeutics, Inc. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported net loss of $9,689,000 or $0.63 basic and diluted loss per share against $2,775,000 or $8.12 basic and diluted loss per share a year ago. Loss from operations was $9,736,000 against $2,160,000 a year ago. For full year, the company reported net loss of $26,088,000 or $3.31 basic and diluted loss per share against $11,742,000 or $36.31 basic and diluted loss per share a year ago. Loss from operations was $22,759,000 against $10,204,000 a year ago. The company provided cash flow guidance for the full year 2014. For the period, the company expects net cash used in operating activities to be approximately $35 to $40 million. In March 2014, the company expected to initiate the ETC-1002-009 Phase 2b clinical study of parallel doses of ETC-1002 over 12 weeks added on to statin therapy in patients with elevated levels of LDL-cholesterol. This study is designed to demonstrate the ability of ETC-1002 to achieve incremental LDL-cholesterol lowering in approximately 132 patients with elevated levels of LDL-cholesterol.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ESPR:US $13.76 USD -0.06

ESPR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ESPR.
View Industry Companies
 

Industry Analysis

ESPR

Industry Average

Valuation ESPR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ESPERION THERAPEUTICS INC, please visit www.esperion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.